UPDATE – 2022 Canadian Urological Association recommendations on prostate cancer screening and early diagnosis:Endorsement of the 2021 Cancer Care Ontario guidelines on prostate multiparametric magnetic resonance imaging – Summary of changes

Ross J. Mason; Karim Marzouk; Antonio Finelli; Fred Saad; Alan I. So; Phillipe D. Violette; Rodney H. Breau; Ricardo A. Rendon

doi:10.5489/CUAJ.7832

UPDATE – 2022 Canadian Urological Association recommendations on prostate cancer screening and early diagnosis:Endorsement of the 2021 Cancer Care Ontario guidelines on prostate multiparametric magnetic resonance imaging – Summary of changes

Ross J. Mason, Karim Marzouk, Antonio Finelli, Fred Saad, Alan I. So, Phillipe D. Violette, Rodney H. Breau, Ricardo A. Rendon

Medicine

Research output: Contribution to journal › Comment/debate › peer-review

1 Citation (Scopus)

Original language	English
Pages (from-to)	86-87
Number of pages	2
Journal	Yosetsu Gakkai Shi/Journal of the Japan Welding Society
Volume	16
Issue number	4
DOIs	https://doi.org/10.5489/CUAJ.7832
Publication status	Published - 2022

Bibliographical note

Funding Information:
Competing interests: Dr. Mason has participated in advisory boards and has been a speaker for Abbvie, Sanofi, TerSera, and Verity. Dr. Saad has received honoraria from Astellas, AstraZeneca, Bayer, Janssen, Knight, Myovant, Novartis, Sanofi, and Pfizer. Dr. So has participated in advisory boards for Abbvie, Amgen, Bayer, Ferring, Janssen, Merck, and TerSera. Dr. Rendon has participated in advisory boards for Abbvie, Amgen, Astellas, AstraZeneca, Bayer, Ferring, Janssen, Pfizer, Roche, Sanofi, and Tolmar; has been a speaker for Abbvie, Amgen, Astellas, AstraZeneca, Bayer, Ferring, Janssen, Pfizer, Roche, and Sanofi; has received grants and/or honoraria from Abbvie, Astellas, Bayer, Ferring, Janssen, Sanofi, Tolmar, and TerSera; holds investments in Myovant; and has participated in clinical trials supported by Abbvie, Astellas, Bavarian Nordic, Bayer, Ferring, Janssen, Myovant, and Sanofi. The remaining authors do not report any competing personal or financial interests related to this work.

ASJC Scopus Subject Areas

Mechanics of Materials
Mechanical Engineering
Surfaces, Coatings and Films
Metals and Alloys

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.5489/CUAJ.7832

Cite this

Mason, R. J., Marzouk, K., Finelli, A., Saad, F., So, A. I., Violette, P. D., Breau, R. H., & Rendon, R. A. (2022). UPDATE – 2022 Canadian Urological Association recommendations on prostate cancer screening and early diagnosis:Endorsement of the 2021 Cancer Care Ontario guidelines on prostate multiparametric magnetic resonance imaging – Summary of changes. Yosetsu Gakkai Shi/Journal of the Japan Welding Society, 16(4), 86-87. https://doi.org/10.5489/CUAJ.7832

UPDATE – 2022 Canadian Urological Association recommendations on prostate cancer screening and early diagnosis:Endorsement of the 2021 Cancer Care Ontario guidelines on prostate multiparametric magnetic resonance imaging – Summary of changes. / Mason, Ross J.; Marzouk, Karim; Finelli, Antonio et al.
In: Yosetsu Gakkai Shi/Journal of the Japan Welding Society, Vol. 16, No. 4, 2022, p. 86-87.

Research output: Contribution to journal › Comment/debate › peer-review

Mason, RJ, Marzouk, K, Finelli, A, Saad, F, So, AI, Violette, PD, Breau, RH & Rendon, RA 2022, 'UPDATE – 2022 Canadian Urological Association recommendations on prostate cancer screening and early diagnosis:Endorsement of the 2021 Cancer Care Ontario guidelines on prostate multiparametric magnetic resonance imaging – Summary of changes', Yosetsu Gakkai Shi/Journal of the Japan Welding Society, vol. 16, no. 4, pp. 86-87. https://doi.org/10.5489/CUAJ.7832

Mason RJ, Marzouk K, Finelli A, Saad F, So AI, Violette PD et al. UPDATE – 2022 Canadian Urological Association recommendations on prostate cancer screening and early diagnosis:Endorsement of the 2021 Cancer Care Ontario guidelines on prostate multiparametric magnetic resonance imaging – Summary of changes. Yosetsu Gakkai Shi/Journal of the Japan Welding Society. 2022;16(4):86-87. doi: 10.5489/CUAJ.7832

Mason, Ross J. ; Marzouk, Karim ; Finelli, Antonio et al. / UPDATE – 2022 Canadian Urological Association recommendations on prostate cancer screening and early diagnosis:Endorsement of the 2021 Cancer Care Ontario guidelines on prostate multiparametric magnetic resonance imaging – Summary of changes. In: Yosetsu Gakkai Shi/Journal of the Japan Welding Society. 2022 ; Vol. 16, No. 4. pp. 86-87.

@article{a66305bc792e43eca7445f5d56c0bcf3,

title = "UPDATE – 2022 Canadian Urological Association recommendations on prostate cancer screening and early diagnosis:Endorsement of the 2021 Cancer Care Ontario guidelines on prostate multiparametric magnetic resonance imaging – Summary of changes",

author = "Mason, {Ross J.} and Karim Marzouk and Antonio Finelli and Fred Saad and So, {Alan I.} and Violette, {Phillipe D.} and Breau, {Rodney H.} and Rendon, {Ricardo A.}",

note = "Funding Information: Competing interests: Dr. Mason has participated in advisory boards and has been a speaker for Abbvie, Sanofi, TerSera, and Verity. Dr. Saad has received honoraria from Astellas, AstraZeneca, Bayer, Janssen, Knight, Myovant, Novartis, Sanofi, and Pfizer. Dr. So has participated in advisory boards for Abbvie, Amgen, Bayer, Ferring, Janssen, Merck, and TerSera. Dr. Rendon has participated in advisory boards for Abbvie, Amgen, Astellas, AstraZeneca, Bayer, Ferring, Janssen, Pfizer, Roche, Sanofi, and Tolmar; has been a speaker for Abbvie, Amgen, Astellas, AstraZeneca, Bayer, Ferring, Janssen, Pfizer, Roche, and Sanofi; has received grants and/or honoraria from Abbvie, Astellas, Bayer, Ferring, Janssen, Sanofi, Tolmar, and TerSera; holds investments in Myovant; and has participated in clinical trials supported by Abbvie, Astellas, Bavarian Nordic, Bayer, Ferring, Janssen, Myovant, and Sanofi. The remaining authors do not report any competing personal or financial interests related to this work.",

year = "2022",

doi = "10.5489/CUAJ.7832",

language = "English",

volume = "16",

pages = "86--87",

journal = "Yosetsu Gakkai Shi/Journal of the Japan Welding Society",

issn = "0021-4787",

publisher = "Japan Welding Society",

number = "4",

}

TY - JOUR

T1 - UPDATE – 2022 Canadian Urological Association recommendations on prostate cancer screening and early diagnosis:Endorsement of the 2021 Cancer Care Ontario guidelines on prostate multiparametric magnetic resonance imaging – Summary of changes

AU - Mason, Ross J.

AU - Marzouk, Karim

AU - Finelli, Antonio

AU - Saad, Fred

AU - So, Alan I.

AU - Violette, Phillipe D.

AU - Breau, Rodney H.

AU - Rendon, Ricardo A.

N1 - Funding Information: Competing interests: Dr. Mason has participated in advisory boards and has been a speaker for Abbvie, Sanofi, TerSera, and Verity. Dr. Saad has received honoraria from Astellas, AstraZeneca, Bayer, Janssen, Knight, Myovant, Novartis, Sanofi, and Pfizer. Dr. So has participated in advisory boards for Abbvie, Amgen, Bayer, Ferring, Janssen, Merck, and TerSera. Dr. Rendon has participated in advisory boards for Abbvie, Amgen, Astellas, AstraZeneca, Bayer, Ferring, Janssen, Pfizer, Roche, Sanofi, and Tolmar; has been a speaker for Abbvie, Amgen, Astellas, AstraZeneca, Bayer, Ferring, Janssen, Pfizer, Roche, and Sanofi; has received grants and/or honoraria from Abbvie, Astellas, Bayer, Ferring, Janssen, Sanofi, Tolmar, and TerSera; holds investments in Myovant; and has participated in clinical trials supported by Abbvie, Astellas, Bavarian Nordic, Bayer, Ferring, Janssen, Myovant, and Sanofi. The remaining authors do not report any competing personal or financial interests related to this work.

PY - 2022

Y1 - 2022

UR - http://www.scopus.com/inward/record.url?scp=85130616924&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85130616924&partnerID=8YFLogxK

U2 - 10.5489/CUAJ.7832

DO - 10.5489/CUAJ.7832

M3 - Comment/debate

AN - SCOPUS:85130616924

SN - 0021-4787

VL - 16

SP - 86

EP - 87

JO - Yosetsu Gakkai Shi/Journal of the Japan Welding Society

JF - Yosetsu Gakkai Shi/Journal of the Japan Welding Society

IS - 4

ER -

UPDATE – 2022 Canadian Urological Association recommendations on prostate cancer screening and early diagnosis:Endorsement of the 2021 Cancer Care Ontario guidelines on prostate multiparametric magnetic resonance imaging – Summary of changes

Bibliographical note

ASJC Scopus Subject Areas

UN SDGs

Access to Document

Other files and links

Cite this